The modest activity observed in these clinical studies has been explained in two ways: First, blockade of PI3K/AKT/mTORC1 pathway induces autophagy [329, 330], which can serve as a protective mechanism to mitigate the cytotoxicity of drugs targeting the PI3K/AKT/mTORC1 pathway in DLBCL cells [329]. This evidence concerns the gene PIK3CD and diffuse large B-cell lymphoma.